Julian Taugner1, Lukas Käsmann1,2,3, Chukwuka Eze1,2, Maurice Dantes1,2, Olarn Roengvoraphoj1, Kathrin Gennen1, Monika Karin1, Oleg Petruknov1, Amanda Tufman2,4, Claus Belka1, Farkhad Manapov1,2. 1. Department of Radiation Oncology, University Hospital Munich (LMU), München, Germany. 2. Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany. 3. German Cancer Consortium (DKTK), partner site Munich, Munich, Germany. 4. Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V, Thoracic Oncology Centre Munich, Ludwig-Maximilians University, München, Germany.
Abstract
BACKGROUND: Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy. METHODS: The data of 99 consecutive patients with performance status ECOG 0-1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7th edition stage IIIA/B) were evaluated. Patient- and tumor-related factors were examined for their impact on overall survival. Factors showing a negative association with prognosis were then included in the score. Three subgroups with low, intermediate and high-risk score were defined. The results were then validated in the prospective cohort, which includes 45 patients. RESULTS: Most Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3-26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0-1 points), intermediate (2-3 points) and high-risk (4-5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P<0.001). Median survival was not reached in prospective cohort; analysis has revealed a trend for the 1-year survival rates with 100% for the low, 93% intermediate and 69% high-risk patients (P=0.100). CONCLUSIONS: The score demonstrated remarkable survival differences in inoperable stage III NSCLC patients with good performance status receiving multimodal therapy. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy. METHODS: The data of 99 consecutive patients with performance status ECOG 0-1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7th edition stage IIIA/B) were evaluated. Patient- and tumor-related factors were examined for their impact on overall survival. Factors showing a negative association with prognosis were then included in the score. Three subgroups with low, intermediate and high-risk score were defined. The results were then validated in the prospective cohort, which includes 45 patients. RESULTS: Most Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3-26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0-1 points), intermediate (2-3 points) and high-risk (4-5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P<0.001). Median survival was not reached in prospective cohort; analysis has revealed a trend for the 1-year survival rates with 100% for the low, 93% intermediate and 69% high-risk patients (P=0.100). CONCLUSIONS: The score demonstrated remarkable survival differences in inoperable stage III NSCLC patients with good performance status receiving multimodal therapy. 2019 Translational Lung Cancer Research. All rights reserved.
Authors: Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome Journal: J Thorac Oncol Date: 2015-11 Impact factor: 15.609
Authors: Andreas Hallqvist; Stefan Bergström; Hedvig Björkestrand; Anna-Maja Svärd; Simon Ekman; Erik Lundin; Erik Holmberg; Mikael Johansson; Signe Friesland; Jan Nyman Journal: Lung Cancer Date: 2018-06-18 Impact factor: 5.705
Authors: Edith M T Dieleman; Apollonia L J Uitterhoeve; Meike W van Hoek; Rob M van Os; Jan Wiersma; Mia G J Koolen; Merel Willemijn Kolff; Caro C E Koning; Judit A Adam; Hein J Verberne; Jouke T Annema; Coen R N Rasch Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-25 Impact factor: 7.038
Authors: Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Erqi L Pollom; Yushen Qian; Ben Y Durkee; Rie von Eyben; Peter G Maxim; David B Shultz; Michael Gensheimer; Maximilian Diehn; Billy W Loo Journal: Clin Lung Cancer Date: 2016-06-08 Impact factor: 4.785
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Marliese Alexander; Rory Wolfe; David Ball; Matthew Conron; Robert G Stirling; Benjamin Solomon; Michael MacManus; Ann Officer; Sameer Karnam; Kate Burbury; Sue M Evans Journal: Br J Cancer Date: 2017-07-20 Impact factor: 7.640
Authors: Lukas Käsmann; Julian Taugner; Chukwuka Eze; Alexander Nieto; Carolyn Pelikan; Benedikt Flörsch; Saskia Kenndoff; Thomas P Hofer; Elfriede Nössner; Christian Schulz; Marcus Unterrainer; Amanda Tufman; Frederick Klauschen; Andreas Jung; Jens Neumann; Jörg Kumbrink; Niels Reinmuth; Peter Bartenstein; Claus Belka; Farkhad Manapov Journal: Transl Lung Cancer Res Date: 2022-07